Better life through medicine-let's leave no one behind.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.PloS one · 2017
   Pooled it
2. Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands.The European journal of health economics : HEPAC : health economics in prevention and care · 2021
   Article
3. Pharmaceutical expenditure control in Europe: time to move from pricing to budgeting?Journal of the Royal Society of Medicine · 2020
   Review
4. Precision medicine and monoclonal antibodies: breach of promise?Croatian medical journal · 2019
   Article
5. Pharmaceutical pricing conundrum: time to get rid of it?The European journal of health economics : HEPAC : health economics in prevention and care · 2018
   Article
6. Defining Success in Open Science [version 2; peer review:2 approved].MNI open research · 2018
   Article
7. Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union:Journal of pharmaceutical policy and practice · 2017
   Review
8. A Healthy Sense of Trust.Biomedicine hub
   Review

Corrections and comments

• Comment on
  Youth demand action on the shared global challenge of access to medicines.2017
• Comment on
  Towards access 2030.2017
• Comment on
  Scaling up for universal health coverage.2017
• Comment on
  Essential medicines for universal health coverage.2017

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as